ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 117 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $291,136 | -69.9% | 10,835 | -71.5% | 0.00% | -66.7% |
| Q1 2023 | $965,835 | -39.2% | 38,025 | -2.9% | 0.00% | -50.0% |
| Q4 2022 | $1,588,127 | +694.1% | 39,155 | +801.8% | 0.01% | +500.0% |
| Q1 2022 | $200,000 | -89.6% | 4,342 | -82.6% | 0.00% | -87.5% |
| Q4 2020 | $1,916,000 | +75.8% | 24,971 | -1.4% | 0.01% | +100.0% |
| Q3 2020 | $1,090,000 | -83.4% | 25,319 | -83.4% | 0.00% | -87.9% |
| Q2 2020 | $6,583,000 | +297.8% | 152,418 | +165.0% | 0.03% | +200.0% |
| Q1 2020 | $1,655,000 | -87.4% | 57,514 | -72.3% | 0.01% | -74.4% |
| Q4 2019 | $13,171,000 | +293.0% | 207,649 | +74.6% | 0.04% | +258.3% |
| Q3 2019 | $3,351,000 | +524.0% | 118,924 | +487.2% | 0.01% | +500.0% |
| Q2 2019 | $537,000 | +66.8% | 20,254 | +20.7% | 0.00% | +100.0% |
| Q3 2018 | $322,000 | +107.7% | 16,785 | +47.5% | 0.00% | 0.0% |
| Q2 2018 | $155,000 | – | 11,377 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |